X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The partnership will pave the way for clinical studies of PneumoBlast™ in Brazil as a unique treatment of acute respiratory distress syndrome (ARDS) for patients affected by COVID-19, in parallel to clinical studies in the United States upon approval by the FDA.
Lead Product(s): PneumoBlast
Therapeutic Area: Infections and Infectious Diseases Product Name: PneumoBlast
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: R4D Biotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 01, 2020
Details:
Study showed that was observed that treatment of activated monocytes with PneumoBlast™ resulted in a 77% reduction of tissue factor expression as compared to untreated monocytes.
Lead Product(s): PneumoBlast
Therapeutic Area: Infections and Infectious Diseases Product Name: PneumoBlast
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 12, 2020
Details:
Company scientists have demonstrated the administration and use of PneumoBlast™ induced a 51% reduction of lung fibrosis, which was statistically significant.
Lead Product(s): PneumoBlast
Therapeutic Area: Infections and Infectious Diseases Product Name: PneumoBlast
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2020
Details:
Administration of PneumoBlast™ resulted in significant reduction in lung fluid accumulation in mice stimulated to enter hyper-activation mode. Also, reduction was observed from inflammatory cells, as well as suppression of chemical mediators such as interleukin-6.
Lead Product(s): PneumoBlast
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2020
Details:
Company reports potent synergy between its fibroblast-based cell therapy and hydroxychloroquine .
Lead Product(s): Fibroblast cells,Hydroxychloroquine Sulphate,Peptides
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
